Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide

The drug–drug interaction (DDI) potential between the fixed‐dose combinations of ledipasvir/sofosbuvir 90/400 mg for hepatitis C virus and emtricitabine/rilpivirine/tenofovir alafenamide (TAF) 200/25/25 mg for HIV was evaluated in a randomized, open‐label, single‐center, multiple‐dose, 3‐way, 6‐sequ...

Descripción completa

Detalles Bibliográficos
Autores principales: Custodio, Joseph M., Chuck, Susan K., Chu, Hoa, Cao, Huyen, Ma, Grace, Flaherty, John, Ling, John, Kearney, Brian P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625157/
https://www.ncbi.nlm.nih.gov/pubmed/28971607
http://dx.doi.org/10.1002/prp2.353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625157/
https://www.ncbi.nlm.nih.gov/pubmed/28971607
http://dx.doi.org/10.1002/prp2.353

Ejemplares similares